Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMID 19790142)

Published in Liver Transpl on October 01, 2009

Authors

Francesco D'Amico1, Myron Schwartz, Alessandro Vitale, Parissa Tabrizian, Sasan Roayaie, Swan Thung, Maria Guido, Juan del Rio Martin, Thomas Schiano, Umberto Cillo

Author Affiliations

1: Hepatobiliary Surgery and Liver Transplant Unit, Department of General Surgery and Organ Transplantation, University of Padua, Padua, Italy. drdamico@hotmail.com

Articles citing this

Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87

Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14

Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06

Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant (2010) 0.93

Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis. Gastroenterol Res Pract (2015) 0.85

Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82

Liver Transplantation for HCC: A Review. Indian J Surg (2011) 0.82

Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol (2016) 0.78

Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol (2013) 0.78

Evaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA-positive cancer-associated fibroblasts. Oncol Rep (2013) 0.77

Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol (2015) 0.77

Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer (2016) 0.75

Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients. Oncotarget (2016) 0.75

Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience. World J Transplant (2016) 0.75

Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation. Mol Clin Oncol (2017) 0.75

Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol (2017) 0.75

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Transplant tourism in China: a tale of two transplants. Am J Bioeth (2010) 6.67

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology (2010) 3.53

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13

Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62

Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol (2006) 2.61

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol (2008) 2.36

Management of hernias in pregnancy. J Am Coll Surg (2008) 2.36

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. J Surg Oncol (2007) 2.25

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22

Factors that predict outcome of abdominal operations in patients with advanced cirrhosis. Clin Gastroenterol Hepatol (2009) 2.18

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18

When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15

Long-term outcome of bone mineral density in children who underwent a successful liver transplantation. Transplantation (2004) 2.04

Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol (2011) 2.04

A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl (2007) 2.01

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95

A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90

Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl (2012) 1.90

Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88

Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int (2012) 1.87

A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2009) 1.78

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77

Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase? Liver Transpl (2009) 1.75

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70

Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65

Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl (2009) 1.60

Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59

Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol (2007) 1.56

An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer (2010) 1.55

Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54

The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis (2010) 1.53

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53

Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53

Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl (2007) 1.52

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology (2008) 1.52

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52

The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int (2010) 1.51

Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl (2012) 1.49

Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol (2009) 1.48

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl (2014) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45